Use of Insulin Pump Therapy in the Pediatric Age-Group: Consensus statement from the European Society for Paediatric Endocrinology, the Lawson Wilkins Pediatric Endocrine Society, and the International Society for Pediatric and Adolescent Diabetes, endorsed by the American Diabetes Association and the European Association for the Study of Diabetes

To address these issues, the European Society for Pediatric Endocrinology (ESPE), the Lawson Wilkins Pediatric Endocrine Society (LWPES), and the International Society for Pediatric and Adolescent Diabetes (ISPAD) convened a panel of expert physicians for a consensus conference endorsed by the Ameri...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes care Vol. 30; no. 6; pp. 1653 - 1662
Main Authors: Phillip, Moshe, Battelino, Tadej, Rodriguez, Henry, Danne, Thomas, Kaufman, Francine
Format: Journal Article
Language:English
Published: Alexandria, VA American Diabetes Association 01.06.2007
Subjects:
Adolescent
Biological and medical sciences
Care and treatment
Child
Children & youth
Costs
Diabetes
Diabetes in children
Diabetes Mellitus, Type 1 - drug therapy
Diabetes. Impaired glucose tolerance
Drug therapy
Endocrine pancreas. Apud cells (diseases)
Endocrinology
Endocrinopathies
Etiopathogenesis. Screening. Investigations. Target tissue resistance
Europe
General aspects
Health aspects
Humans
Hypoglycemia
Insulin
Insulin Infusion Systems
Insulin pumps
Medical sciences
Miscellaneous
Pediatrics
Public health. Hygiene
Public health. Hygiene-occupational medicine
Risk
Societies, Medical
Studies
United States
World
Europe
United States
Endocrinopathy
Human
Pediatrics
Therapy
Endocrine gland
Diabetes mellitus
Use
Consensus
Treatment
Insulin pump
Adolescent
Child
Age
Endocrinology
Public health
International
ISSN:0149-5992, 1935-5548, 1935-5548
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To address these issues, the European Society for Pediatric Endocrinology (ESPE), the Lawson Wilkins Pediatric Endocrine Society (LWPES), and the International Society for Pediatric and Adolescent Diabetes (ISPAD) convened a panel of expert physicians for a consensus conference endorsed by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). The following variables should be considered in analyzing the cost benefit of CSII: acute complications, i.e., the frequency of severe hypoglycemia and DKA (including emergency department visits and hospitalizations [C: 58]); chronic complications, both micro- and macrovascular (EDIC macrovascular study [B: 95]); direct costs of supplies; indirect costs related to lost earnings of parents; and costs of other caregivers and additional care team resources.
Bibliography:SourceType-Scholarly Journals-1
ObjectType-News-1
content type line 14
ObjectType-Conference-2
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ObjectType-Conference-1
ISSN:0149-5992
1935-5548
1935-5548
DOI:10.2337/dc07-9922